PMID- 24598068
OWN - NLM
STAT- MEDLINE
DCOM- 20140903
LR  - 20191112
IS  - 1349-7413 (Electronic)
IS  - 0911-4300 (Linking)
VI  - 37
IP  - 1
DP  - 2014
TI  - [Analysis of the relationship between polymyalgia rheumatica and matrix 
      metalloproteinase-3 levels during the first medical examination and during 
      treatment].
PG  - 48-54
AB  - In the present study, we assessed the relationship between polymyalgia rheumatica 
      (PMR) and matrix metalloproteinase-3 (MMP-3) levels during the first medical 
      examination and during treatment. We examined 22 patients with PMR in our 
      hospital from 2010 to 2012, in whom the diagnosis was confirmed by the 2012 
      Provisional Classification Criteria for PMR. The MMP-3 levels were obtained from 
      19 patients, and the average MMP-3 level was 200.8 ng/mL; this level increased in 
      15 patients. During the 1 month after treatment initiation, the average dose of 
      prednisolones (PSL) was increased from 2.75 mg/day to 11.3 mg/day, whereas the 
      C-reactive protein level decreased from 6.92 mg/dL to 0.33 mg/dL; however, the 
      average MMP-3 levels increased to 225.1 ng/mL during this period. When comparing 
      the 7 patients in whom PSL withdrawal was achieved within 1 year and the patients 
      in whom PSL withdrawal was difficult, we noted that the MMP-3 levels were higher 
      in the patients in whom PSL withdrawal was difficult, and the MMP-3 level at 3 
      months after the first medical examination was significantly higher compared to 
      the MMP-3 level during the first medical examination (p = 0.011). Although the 
      MMP-3 level is influenced by PSL use, the MMP-3 levels may be considered to 
      reflect the disease activity of PMR. Thus, MMP-3 levels may be a useful 
      predictive factor for the success of PSL withdrawal in patients with PMR.
FAU - Miyake, Kouhei
AU  - Miyake K
AD  - Department of Internal Medicine, Chugoku central hospital, Mutual Aid Association 
      of Public School Teachers.
FAU - Katsuyama, Takayuki
AU  - Katsuyama T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho Meneki Gakkai Kaishi
JT  - Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology
JID - 9505992
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - C-Reactive Protein/analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Polymyalgia Rheumatica/*blood/*drug therapy
MH  - Prednisolone/administration & dosage
EDAT- 2014/03/07 06:00
MHDA- 2014/09/04 06:00
CRDT- 2014/03/07 06:00
PHST- 2014/03/07 06:00 [entrez]
PHST- 2014/03/07 06:00 [pubmed]
PHST- 2014/09/04 06:00 [medline]
AID - DN/JST.JSTAGE/jsci/37.48 [pii]
AID - 10.2177/jsci.37.48 [doi]
PST - ppublish
SO  - Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(1):48-54. doi: 10.2177/jsci.37.48.